[go: up one dir, main page]

WO1999021541A3 - Traitement des lesions ischemiques par des transporteurs d'oxygene synthetiques - Google Patents

Traitement des lesions ischemiques par des transporteurs d'oxygene synthetiques Download PDF

Info

Publication number
WO1999021541A3
WO1999021541A3 PCT/US1998/022491 US9822491W WO9921541A3 WO 1999021541 A3 WO1999021541 A3 WO 1999021541A3 US 9822491 W US9822491 W US 9822491W WO 9921541 A3 WO9921541 A3 WO 9921541A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthetic oxygen
oxygen carrier
amelioration
synthetic
ischemic damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/022491
Other languages
English (en)
Other versions
WO1999021541A2 (fr
Inventor
Peter E Keipert
N Simon Faithfull
Stephen F Flaim
Gwen H Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alliance Pharmaceutical Corp
Original Assignee
Alliance Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharmaceutical Corp filed Critical Alliance Pharmaceutical Corp
Priority to US09/530,075 priority Critical patent/US6679859B1/en
Priority to AU11179/99A priority patent/AU1117999A/en
Priority to EP98953931A priority patent/EP1023058A2/fr
Publication of WO1999021541A2 publication Critical patent/WO1999021541A2/fr
Publication of WO1999021541A3 publication Critical patent/WO1999021541A3/fr
Anticipated expiration legal-status Critical
Priority to US10/760,572 priority patent/US20050049359A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une technique qui permet de traiter les lésions tissulaires d'origine hypoxique ou ischémique en administrant par voie générale un transporteur d'oxygène synthétique à un individu qui présente une obstruction vasculaire ou chez qui l'on suspecte la présence d'une obstruction vasculaire. Elle concerne également un transporteur d'oxygène compris dans un véhicule physiologiquement acceptable et constitué de particules submicroniques capables de traverser des vaisseaux sanguins obstrués par des emboles. De préférence, ledit transporteur d'oxygène est une émulsion de fluorocarbure, un succédané du sang cristallisé, un succédané du sang colloïde ou une combinaison desdits éléments.
PCT/US1998/022491 1997-10-24 1998-10-23 Traitement des lesions ischemiques par des transporteurs d'oxygene synthetiques Ceased WO1999021541A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/530,075 US6679859B1 (en) 1997-10-24 1998-10-23 Amelioration of ischemic damage using synthetic oxygen carriers
AU11179/99A AU1117999A (en) 1997-10-24 1998-10-23 Amelioration of ischemic damage using synthetic oxygen carriers
EP98953931A EP1023058A2 (fr) 1997-10-24 1998-10-23 Traitement des lesions ischemiques par des transporteurs d'oxygene synthetiques
US10/760,572 US20050049359A1 (en) 1998-10-23 2004-01-20 Amelioration of ischemic damage using synthetic oxygen carriers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6350297P 1997-10-24 1997-10-24
US60/063,502 1997-10-24

Publications (2)

Publication Number Publication Date
WO1999021541A2 WO1999021541A2 (fr) 1999-05-06
WO1999021541A3 true WO1999021541A3 (fr) 1999-08-05

Family

ID=22049637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022491 Ceased WO1999021541A2 (fr) 1997-10-24 1998-10-23 Traitement des lesions ischemiques par des transporteurs d'oxygene synthetiques

Country Status (3)

Country Link
EP (1) EP1023058A2 (fr)
AU (1) AU1117999A (fr)
WO (1) WO1999021541A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60020556T2 (de) 1999-05-12 2005-10-27 Neurosearch A/S Ionenkanal modulierende mittel
GB9919131D0 (en) * 1999-08-14 1999-10-13 Depuy Int Ltd Joint lubrication
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US7794699B2 (en) 2005-01-05 2010-09-14 Michigan Molecular Institute Nano-structured blood substitutes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037992A1 (fr) * 1980-04-14 1981-10-21 Thomas Jefferson University Liquide cérébrospinal, méthode de fabrication d'un tel liquide et appareil destiné à sa mise en oeuvre
EP0088954A2 (fr) * 1982-03-03 1983-09-21 Thomas Jefferson University Appareil pour utilisation dans le traitement de l'apoplexie utilisant la circulation extravasculaire d'un liquide alimentaire synthétique oxygéné pour le traitement de désordres hypoxiques et ischémiques tissulaires
US5085630A (en) * 1980-04-14 1992-02-04 Thomas Jefferson University Oxygenated fluorocarbon nutrient solution
WO1992010221A2 (fr) * 1990-12-14 1992-06-25 Mallinckrodt Medical, Inc. Systeme et procede d'oxygenation du c×ur utilisant des liquides sous-pericardiques
WO1996040057A2 (fr) * 1995-06-07 1996-12-19 Alliance Pharmaceutical Corp. Compositions a emulsions de fluorocarbone inverses pour l'administration de medicaments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037992A1 (fr) * 1980-04-14 1981-10-21 Thomas Jefferson University Liquide cérébrospinal, méthode de fabrication d'un tel liquide et appareil destiné à sa mise en oeuvre
US5085630A (en) * 1980-04-14 1992-02-04 Thomas Jefferson University Oxygenated fluorocarbon nutrient solution
EP0088954A2 (fr) * 1982-03-03 1983-09-21 Thomas Jefferson University Appareil pour utilisation dans le traitement de l'apoplexie utilisant la circulation extravasculaire d'un liquide alimentaire synthétique oxygéné pour le traitement de désordres hypoxiques et ischémiques tissulaires
WO1992010221A2 (fr) * 1990-12-14 1992-06-25 Mallinckrodt Medical, Inc. Systeme et procede d'oxygenation du c×ur utilisant des liquides sous-pericardiques
WO1996040057A2 (fr) * 1995-06-07 1996-12-19 Alliance Pharmaceutical Corp. Compositions a emulsions de fluorocarbone inverses pour l'administration de medicaments

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DEL BALZO, U. ET AL: "Perflubron emulsion: Effect on post- ischemic ventricular function in the isolated rabbit heart.", JOURNAL OF INVESTIGATIVE MEDICINE, (1996) VOL. 44, NO. 7, PP. 415A. MEETING INFO.: MEETING OF THE EASTERN SECTION OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH BOSTON, MASSACHUSETTS, USA OCTOBER 4-5, 1996 ISSN: 1081-5589., XP002104381 *
HALE, S. L. ET AL: "Effect of two perfluorocarbon emulsions on reperfusion injury after coronary artery occlusion in rabbits", BASIC RES. CARDIOL. (1995), VOLUME DATE 1995, 90(5), 404-9 CODEN: BRCAB7;ISSN: 0300-8428, XP002104379 *
MOSCA R S ET AL: "Perfluorocarbon supplementation and postischemic cardiac function.", SURGERY, (1996 AUG) 120 (2) 197-204. JOURNAL CODE: VC3. ISSN: 0039-6060., United States, XP002104380 *
SYMONS, J. D. ET AL: "Perflubron emulsion increases tolerance to myocardial ischemia in the isolated rabbit heart.", FASEB JOURNAL, (1995) VOL. 9, NO. 3, PP. A622. MEETING INFO.: EXPERIMENTAL BIOLOGY 95, PART I ATLANTA, GEORGIA, USA APRI 9-13, 1995 ISSN: 0892-6638., XP002104378 *
VOIGLIO, ERIC J. ET AL: "Aerobic preservation of organs using a new perflubron /lecithin emulsion stabilized by molecular dowels", J. SURG. RES. (1996), 63(2), 439-446 CODEN: JSGRA2;ISSN: 0022-4804, XP002104382 *

Also Published As

Publication number Publication date
WO1999021541A2 (fr) 1999-05-06
AU1117999A (en) 1999-05-17
EP1023058A2 (fr) 2000-08-02

Similar Documents

Publication Publication Date Title
IS4675A (is) Örþeytur til að nota sem burðarefni við inngjöf virkra efna
CA2161191A1 (fr) Produit pour application topique contenant une lipase et un precurseur d'actif
CA2008907A1 (fr) Catalyseurs pour la polymerisation d'olefines
TW349882B (en) Catalyst and process for the preparation of hydrocarbons
CA2311696A1 (fr) Composition de bronzage renfermant du carmin
CA2213887A1 (fr) Agrafe chirurgicale
AU8775791A (en) 2-substituted bisindenylmetallocenes, process for their preparation, and their use as catalysts in the polymerization of olefins
CA2197432A1 (fr) Formulations liquides d'immunoglobuline
CA2168029A1 (fr) Peptides derives de la prosaposine et de la cytokine, agents therapeutiques
WO1996028132A3 (fr) Gels cosmetiques ou dermatologiques a base de microemulsions
AU3074289A (en) 2,2'-iminobisethanol derivatives as potentiators of the effects of blood pressure reducing agents
CA2159985A1 (fr) Methodes d'utilisation de l'hesperetine pour le controle du sebum et le traitement de l'acne
AU3716297A (en) Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
CA2110161A1 (fr) Preparations transdermiques de medetomidine
CA2004861A1 (fr) Usages dermiques de retinoides non irritants
WO1999021541A3 (fr) Traitement des lesions ischemiques par des transporteurs d'oxygene synthetiques
CA2198852A1 (fr) Solutions parenterales contenant des sulfonamides de 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline
USD317539S (en) Adjustable boating chair pedestal
ES2108295T3 (es) Procedimiento mejorado para la preparacion de acido 3-pentenoico a partir de butadieno.
JPS52110793A (en) Preparation of highly crystalline olefin polymers
CA2255649A1 (fr) Micro-emulsions a base de lecithine contenant des enzymes proteolytiques et technique d'epilation enzymatique permanente
CA2256348A1 (fr) Methode pour ameliorer les problemes cutanes
WO2001077186A3 (fr) Procede de fabrication d'un catalyseur sur support destine a la polymerisation des olefines
BR8903067A (pt) Processo de preparacao de composicao catalitica para polimerizacao de olefinas e composicao catalitica
CA2288080A1 (fr) Procede pour detecter de maniere fonctionnelle des dysfonctionnements dans le systeme de la proteine c

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998953931

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09530075

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998953931

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998953931

Country of ref document: EP